Argos Therapeutics Discusses Novel Solutions for Automated Immunotherapy Manufacturing at ISCT Annual Meeting
The presentation addresses the challenge of optimizing dendritic cell-based therapy that achieves maximum clinical efficacy, as well as the successful commercial production of consistent products. To meet this challenge, Argos has developed working prototypes of equipment capable of automating cellular and RNA processing. These automated devices carry out autologous immunotherapy production at higher throughput and with a lower cost of goods versus manual processing methods. The automated system includes three standalone units: an RNA processing unit and two cellular processing units (designed to perform the various cellular and plasma processing steps) using functionally closed disposables.
"Argos has made major progress toward a commercializeable, automated system that provides a cost-effective solution for our autologous cell immunotherapy products. An automated system for cellular and RNA processing can address a broad range of disease indications amenable to cell-based immunotherapy, including infectious diseases and cancer," said Frederick Miesowicz, Ph.D., Chief Operating Officer of Argos. "Our complementary, proprietary manufacturing capabilities contribute to Argos' leadership in the field of advanced personalized immunotherapy."
Argos' personalized immunotherapy development programs are part of the Company's broad collaboration with Kirin Pharma Company, Ltd.
About Argos Therapeutics, Inc.
Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells - the master switch that turns the immune system on or off. www.argostherapeutics.com
MacDougall Biomedical Communications
Jennifer Greenleaf, 781-235-3060
Jeff Abbey, 919-287-6308
Posted: May 2008